Project Grant R01CA311765
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $603K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- Federal Grant Award Summary Emory University received a $402,401 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. The award funds research investigating the combination of ionizing radiation (IR) and trastuzumab deruxtecan (T-DXD), a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate, to sensitize HER2-negative and HER2-low breast cancers to treatment....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...
- Federal Project Grant Award Summary Emory University received a $572,378 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with a completion date of April 30, 2031. The grant funds fundamental research investigating metabolic gatekeeping mechanisms that regulate dormancy in disseminated non-small cell lung cancer (NSCLC) subpopulations. The research employs an image-guided genomics approach to examine how leader...
- Federal Project Grant Award Summary Emory University received a $646,181 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective April 2, 2026, through March 31, 2031. The grant supports fundamental research investigating the role of clonal hematopoiesis (CH)—an age-related condition affecting over 20% of individuals aged 70 and older—in non-small cell lung cancer (NSCLC) development and progression. The research deliverables...
- Federal Grant Award Summary Emory University received a $639,859 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective May 1, 2026 through April 30, 2031. The award supports research to identify and overcome drug resistance mechanisms in acute myeloid leukemia (AML), a condition in which most patients develop resistance to existing chemotherapy or targeted therapies, leading to disease relapse and mortality. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $402,401 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on April 6, 2026, with completion scheduled for March 31, 2028. This research project targets androgen-driven resistance to immune checkpoint inhibitors (ICIs) in pancreatic ductal adenocarcinoma (PDAC) through a sex-specific therapeutic approach. The research will develop and evaluate improved methods of cancer treatment by...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2028. The award supports fundamental research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugate therapy, specifically examining the drug sacituzumab govitecan (SG), which is approved for...
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...
- Federal Project Grant Award Summary The University of Tennessee Health Science Center received a $658,561 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 7, 2025, with a completion date of July 31, 2030. This award supports research focused on targeted MDM2 (Murine Double Minute 2) degradation as an improved therapeutic strategy for triple-negative breast cancer (TNBC). The project centers on optimization and...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $179,276 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), awarded on December 1, 2025, with a completion date of May 31, 2027. The award supports biomedical research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The grant funds investigator-initiated research examining the...